Avidity Partners Management LP Has $8.09 Million Stock Holdings in Context Therapeutics Inc. $CNTX

Avidity Partners Management LP trimmed its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 38.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,504,855 shares of the company’s stock after selling 3,477,000 shares during the period. Context Therapeutics makes up 2.3% of Avidity Partners Management LP’s portfolio, making the stock its 11th biggest holding. Avidity Partners Management LP owned about 0.06% of Context Therapeutics worth $8,092,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP grew its holdings in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares in the last quarter. State Street Corp grew its holdings in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after purchasing an additional 13,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after purchasing an additional 188,202 shares in the last quarter. Blue Owl Capital Holdings LP grew its holdings in shares of Context Therapeutics by 0.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 3rd quarter worth $100,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CNTX. Piper Sandler increased their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Guggenheim reissued a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Wall Street Zen lowered Context Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.60.

Context Therapeutics Stock Down 2.1%

NASDAQ:CNTX opened at $1.39 on Friday. The stock’s 50-day simple moving average is $2.34 and its 200 day simple moving average is $2.09. The firm has a market capitalization of $127.71 million, a PE ratio of -3.31 and a beta of 1.61. Context Therapeutics Inc. has a twelve month low of $0.56 and a twelve month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, analysts anticipate that Context Therapeutics Inc. will post -0.35 EPS for the current fiscal year.

Context Therapeutics Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.